Want to see TNON full AI Analyst Report?
TNON Stock Chart & Stats
$5.21
>-$0.01(-3.00%)
At close: 4:00 PM EDT
$5.21
>-$0.01(-3.00%)
Day’s Range― - ―
52-Week Range$2.40 - $45.50
Previous Close$0.19
Volume460.08K
Average Volume (3M)11.24M
Market Cap
$6.75M
Enterprise Value$11.30M
Total Cash (Recent Filing)$1.68M
Total Debt (Recent Filing)$5.68M
Price to Earnings (P/E)―
Beta0.01
Next Earnings
Nov 18, 2026EPS Estimate
-5.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-46.30
Shares Outstanding2,688,735
10 Day Avg. Volume220,575
30 Day Avg. Volume11,240,358
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)1.78
P/FCF Ratio-0.64
Enterprise Value/Market Cap1.67
Enterprise Value/Revenue2.12
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda-0.91
Forecast
1Y Price Target
$10.00Price Target Upside91.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-23.75
Revenue Forecast (FY)$6.40M
Bulls Say, Bears Say
Bulls Say
Revenue And Margin ExpansionRapid revenue growth alongside a 21-point gross-margin improvement indicates stronger procedure volumes, field productivity, and operating absorption. If these gains persist, Tenon can build better unit economics and create a more scalable commercial foundation over the next several quarters.
Regulatory And Product ProgressFDA clearance removes a regulatory hurdle and reclassifies certain instruments as reusable, which management expects to lower procedure costs and support margins. The advancing SImmetry+ and other pipeline programs could broaden clinical utility and strengthen product differentiation.
Convertible Notes RetiredEarly repayment removes a significant near-term debt obligation and eliminates the specific possibility of conversion at a discount. This improves capital-structure clarity, reduces one source of dilution, and preserves more flexibility for commercialization and growth planning.
Bears Say
Persistent Operating LossesOperating leverage has not yet materialized: losses remained broadly flat even as revenue doubled and gross profit increased substantially. Unless commercial growth begins to outpace sales, research, and administrative costs, profitability may remain distant and future funding needs may continue.
Ongoing Cash BurnSustained negative operating and free cash flow shows that Tenon is not currently self-funding its operations. Continued cash consumption can constrain investment choices, increase dependence on external capital, and leave the company more exposed if revenue growth or financing access weakens.
Financing And Dilution DependenceRepeated warrant and equity-linked financings provide liquidity but also demonstrate reliance on capital markets to support working capital and expansion. The new warrants create potential future share issuance, so ongoing funding needs may pressure ownership and limit long-term capital-allocation flexibility.
Tenon Medical, Inc. News
TNON FAQ
What was Tenon Medical, Inc.’s price range in the past 12 months?
Tenon Medical, Inc. lowest stock price was $2.40 and its highest was $45.50 in the past 12 months.
What is Tenon Medical, Inc.’s market cap?
Tenon Medical, Inc.’s market cap is $6.75M.
When is Tenon Medical, Inc.’s upcoming earnings report date?
Tenon Medical, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 26 days.
How were Tenon Medical, Inc.’s earnings last quarter?
Tenon Medical, Inc. released its earnings results on Aug 13, 2026. The company reported -$12.35 earnings per share for the quarter, missing the consensus estimate of -$8.4 by -$3.95.
Is Tenon Medical, Inc. overvalued?
According to Wall Street analysts Tenon Medical, Inc.’s price is currently Undervalued.
Does Tenon Medical, Inc. pay dividends?
Tenon Medical, Inc. does not currently pay dividends.
What is Tenon Medical, Inc.’s EPS estimate?
Tenon Medical, Inc.’s EPS estimate is -5.62.
How many shares outstanding does Tenon Medical, Inc. have?
Tenon Medical, Inc. has 2,688,735 shares outstanding.
What happened to Tenon Medical, Inc.’s price movement after its last earnings report?
Tenon Medical, Inc. reported an EPS of -$12.35 in its last earnings report, missing expectations of -$8.4. Following the earnings report the stock price went down -13.423%.
Which hedge fund is a major shareholder of Tenon Medical, Inc.?
Currently, no hedge funds are holding shares in TNON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
TNON Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong operational momentum with record second-quarter revenue, substantial gross profit and margin expansion, FDA clearance for Catamaran, an advancing R&D pipeline, and a $4.2M capital raise to extend runway. These positives are tempered by continued operating losses, higher operating expenses, non-cash interest expenses increasing net loss, and a diminished quarter-end cash balance. However, management has clear near-term catalysts (product launches, reusable instrumentation benefits beginning in Q3, training center momentum) that are likely to drive further progress.View all TNON earnings summariesTNON Stock 12 Month Forecast
Average Price Target
$10.00
▲(91.94% Upside)
Technical Analysis
Strata Skin Sciences
―
Lifeward
―
enVVeno Medical
―
PAVmed
―
Heart Test Laboratories, Inc.
―
Ownership Overview
66.52% Insiders
4.96% Mutual Funds
― Other Institutional Investors
28.45% Public Companies and
Individual Investors